Synthetic cannabinoids / RC noids – how the scene changed over the years

[Slizchem (OP)]

I’ve followed the synthetic cannabinoid side of the RC scene for years, and the biggest thing people sometimes forget is how different the generations really are. Early compounds like JWH-018, JWH-073, AM-2201, UR-144 and XLR-11 were already a completely different experience from cannabis, but later families pushed potency and unpredictability much further. Then came names such as AB-FUBINACA, ADB-FUBINACA, 5F-ADB, 5F-MDMB-PINACA, MDMB-4en-PINACA, 4F-MDMB-BINACA, ADB-BUTINACA and MDMB-BUTINACA. Most people in the scene just call them synthetic cannabinoids, SCs, noids or RC noids, but grouping everything under one label can be misleading because the pharmacology can differ a lot.

What interests me most is how quickly one generation replaces another after bans, and how the shorthand names often tell you less than people think. A compound sharing ADB, MDMB, 5F or PINACA in the name does not automatically mean it will behave like another one from the same family. Many of the newer noids are strong CB1 receptor agonists, often much less forgiving than Δ9-THC, so potency, duration and adverse effects can vary sharply even between closely related structures.

https://t.me/SlizchemRC
slizchem@proton.me

[smfadmin]

Good post, and the point about shorthand is the one that bites people most !

• Head group (AB, ADB, MDMB): the amino-acid-derived end of the molecule.
• Core (indazole or indole): the middle of the molecule, which the -INACA / -ICA endings tell you about.
• Tail (5F, 4F, 4en, FUBINACA, BUTINACA, PINACA): the chain that mostly drives how potent it is and how long it lasts.

Two compounds can share a head group and still behave very differently because the tail has changed. Different head, same tail can be just as misleading. The name tells you the family tree, not what a dose will do.

The bigger gap is between THC and these compounds. THC is a partial agonist at CB1, so there's a ceiling on how hard it can push the receptor. Many of the newer noids are full agonists with much higher efficacy, and there's no CBD or other cannabinoid in the mix to buffer them. That's why the dose-response curve is so steep, and why "I smoke weed, I'll be fine" catches people out.

Preparation makes it worse. On sprayed herbal blends the compound is rarely distributed evenly, so one hit can be many times stronger than the next from the same bag. That unevenness is behind a lot of the bad outcomes: the seizures, the long unresponsive spells, the cardiac stuff. Withdrawal after heavy daily use is also real and gets underestimated, because everyone starts from the assumption that it's just a cannabis substitute.

The turnover after each ban is the part I find most interesting. Every generation replaces the last one before the pharmacology is properly characterised, so users are effectively the first test group every time.

mm As admin, you may want to settle how to handle the Telegram link and email at the bottom of that post before replying, since your reply will sit right next to them.